Weight control is an essential part of treatment for type 2 diabetes (T2D) patients. Weight
loss is associated with decreased haemoglobin A1c (A1c) levels. In particular, visceral fat
is accompanied by more alterations in glucose and lipid metabolism. Quantification of
visceral fat with bioimpedance (BIA) is closely related to measurement with computed axial
tomography. Different available oral antidiabetics cause weight loss and total body fat
(biguanides, DPP-4 inhibitors and SGLT-2 inhibitors), but it has only been shown that SLGT2
inhibitors decrease visceral fat. Therefore, the aim of this study is to determine whether
there is a difference in the amount of visceral fat measured with BIA in T2D patients between
three oral antidiabetic regimens after twelve weeks of treatment, to compare the effect on
visceral fat between metformin, DPP4 inhibitors and SGLT2 inhibitors.
Phase:
N/A
Details
Lead Sponsor:
Metabolic Research Unit
Treatments:
Biguanides Dipeptidyl-Peptidase IV Inhibitors Sodium-Glucose Transporter 2 Inhibitors